Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata lists "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report).
Date of Report: November 14, 2013.
Reporting Period: The filing announces the results of operations for the quarter ended September 30, 2013.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed financial data. The text itself does not contain specific numerical values for:
- Revenue
- Profit or Loss
- Cash Flow
- Margins
- Debt or Liquidity positions
The filing text does not provide a clear value for these metrics; they are contained in the attached Exhibit 99.1 which is not included in the input.
Material Changes
The filing text does not describe specific material changes versus the prior comparable period. It solely confirms the reporting of quarterly results.
Guidance, Outlook, and Risks
Management Commentary: The filing notes that the results were reported via a press release dated November 14, 2013.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Guidance/Risks: No specific guidance, outlook, risks, or contingencies are detailed in the provided text.
Investor Verification Checklist
- Verify the correct registrant name (RXi Pharmaceuticals Corporation vs. Phio Pharmaceuticals Corp. in metadata).
- Review the attached Press Release (Exhibit 99.1) for actual revenue, net loss, and cash position figures for the quarter ended September 30, 2013.
- Confirm if the press release contains updated clinical trial data or regulatory milestones, as these are typical drivers for biopharma 8-K filings.
- Check subsequent filings to see if the results were incorporated by reference into future 10-Q or 10-K reports.